Blue Jet Healthcare Ltd

Blue Jet Healthcare Limited was originally incorporated as Jet Chemicals Private Limited,' at Mumbai, dated December 7, 1968. The Company name was changed to Blue Jet Healthcare Private Limited', and a fresh Certificate of Incorporation dated December 30, 2020, was issued by the Registrar of Companies, Mumbai. Subsequently, the status got converted into a Limited Company and its name was changed to Blue Jet Healthcare Limited' on May 18, 2022. The Company is a global, science-led, pharmaceutical company evolved as strategic partner for Collaboration, Development & Manufacturing of Advance Pharmaceutical Intermediates and API. It operate into 3 product categories, contrast media intermediates, high- intensity sweeteners, and pharma intermediates and active pharmaceutical ingredients (APIs). It is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products. Since incorporation in 1968, the Company was established with the name Jet Chemicals Private Limited' in Shahad (Unit I) by Late Shri B L Arora. At present, Company has been expanded to include contract development and manufacturing organization (CDMO) business model with specialized chemistry capabilities in contrast media intermediates and high intensity. In 1970, the Company began manufacturing saccharin and its salts, which are high-intensity sweeteners. In 2000, it entered the X-ray contrast media sector, with a basic building block (5- NIPA). In 2002, it started manufacturing of pharma intermediates and API. In 2003, it established Blue Circle Organics Private Limited at their Unit-II, Ambernath facility. In 2017, it started semi-automated manufacturing block for their contrast media intermediate business. The National Company Law Tribunal at Mumbai (NCLT), by way of its Order dated November 19, 2020, sanctioned a Scheme of Merger amongst the Company, Blue Circle Organics Private Limited and their respective shareholders, and creditors and made it effective from December 28, 2020. In 2020 it acquired a Unit III brownfield site in Mahad. In 2021, it acquired a Unit IV 'greenfield' manufacturing site in Ambernath. The Company made an Offer for Sale of issuing 24,285,160 Equity Shares of Rs 2/- each by raising funds aggregating to Rs 84 Crore in October, 2023. In 2024, Company launched a new product in the PI/API division for a cardiovascular innovator, with rise in pharmacy benefits. Company commissioned 120 KL of capacity Plant 6 at Unit II (Ambernath) for pharma intermediates and contrast media products in 2025.